Should the U.S. Allow Prescription Drug Reimports from Canada?

2001 ◽  
Author(s):  
Paul Pecorino
Keyword(s):  
Prescription Drug ◽  
The U.S

Medicare Drug Law Has Rorschach Test Features

2003 ◽  
Vol 22 (3) ◽  
pp. 153-165
Author(s):  
Thomas W. Elwood
Keyword(s):  
Prescription Drug ◽  
Political Context ◽  
Rorschach Test ◽  
Drug Law ◽  
The U.S

An analysis of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Its evolvement in the U.S. political context, particularly Congress, and its social ramifications are reviewed.

Technology's Enabling Role to Improve Care Coordination

2020 ◽  
pp. 358-365
Author(s):  
Rima Gibbings ◽  
Nilmini Wickramasinghe
Keyword(s):  
Information Technology ◽  
Drug Interactions ◽  
Patient Care ◽  
Prescription Drug ◽  
Care Coordination ◽  
Healthcare Systems ◽  
Care Plans ◽  
Treatment Services ◽  
Drug Errors ◽  
The U.S

The U.S. healthcare system has been often characterized as fragmented and disconnected. Lack of effective and concurrent adoption of information technology has been known to be a factor that contributes to the decentralization of healthcare systems. Fragmented systems are also responsible for creating silos that operate with minimal coordination. Clinicians in such systems are providing duplicate services because they are not aware of patient care plans set by other practitioners. These duplications could lead to prescription drug errors due to inconsistencies and lack of coordination in the treatment services and in some cases drug-drug interactions. The following suggests a role for technology to facilitate better care coordination.

scholarly journals Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0155035 ◽  
Author(s):  
Helen W. Sullivan ◽  
Kathryn J. Aikin ◽  
Eunice Chung-Davies ◽  
Michael Wade
Keyword(s):  
Prescription Drug ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Drug Promotion ◽  
The U.S

scholarly journals Federal Policy for Lowering Prescription Drug Prices

2020 ◽  
Vol 17 (01) ◽  
Author(s):  
Amanda Hurley ◽  
Celeste M. Sheftel ◽  
Alejandra Canales
Keyword(s):  
Drug Discovery ◽  
Prescription Drug ◽  
Human Services ◽  
Medicare Part D ◽  
Medicare Part ◽  
Presidential Candidate ◽  
Part D ◽  
Health And Human Services ◽  
Drug Prices ◽  
The U.S

Both Republicans and Democrats are determined to lower the escalating cost of prescription drug prices, which is projected to reach $605 billion/yr by 2026 (Committee on Ways and Means 2019). In this memorandum, we explore the possible outcomes of, 1) linking U.S. drug prices to the international median incentivized by re-importation of the U.S.-made drugs from other countries, 2) allowing the Secretary of Health and Human Services (HHS) to negotiate Medicare part D drugs incentivized through patent exemption and, 3) funding drug discovery through prizes instead of market-exclusive patents. We recommend that the next presidential candidate approve Option 2 and advocate for HHS Secretary negotiation powers with patent exemptions for non-compliant companies.

Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation

2021 ◽  
Vol 49 (4) ◽  
pp. 683-687
Author(s):  
Sarosh Nagar ◽  
Aaron S. Kesselheim
Keyword(s):  
Prescription Drug ◽  
Drug Market ◽  
Brand Name ◽  
Market Exclusivity ◽  
Drug Pricing ◽  
The U.S

AbstractBrand-name prescription drug manufacturers use various strategies to extend their market exclusivity periods by delaying generic or biosimilar competition. Recent Congressional legislation has targeted four such tactics. We analyze these proposals and assess their likely effect on competition in the U.S. drug market.

Sign in / Sign up

Export Citation Format

Share Document